Diwakar Davar
Hematology & Oncology · Pittsburgh, PANPI 1295965523
Payments from drug & device makers
Across 1,619 payments — averaging $13,347 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6.9M
- GSK$5.3M
- E.r. Squibb & Sons, L.L.C.$2.7M
- Regeneron$1.8M
- AstraZeneca$1.1M
- Ascendis Pharma Endocrinology Inc$1.1M
- plus $2.7M from 24 others
Across 11 payments — averaging $13,048 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ichnos Glenmark Innovation Inc$140K
- Regeneron$4K
What the payments were for
- Consulting fees$44,52843%
- Speaking & faculty fees$37,35836%
- Travel & lodging$18,06617%
- Food & beverage$4,3994%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 62 | $6,895,711 |
| GSK | 270 | $5,255,920 |
| E.r. Squibb & Sons, L.L.C. | 54 | $2,690,189 |
| Regeneron | 625 | $1,816,951 |
| AstraZeneca | 14 | $1,114,824 |
| Ascendis Pharma Endocrinology Inc | 90 | $1,101,203 |
| Trisalus Life Sciences, Inc. | 59 | $839,060 |
| Immunocore Limited | 227 | $616,014 |
| Tesaro, Inc. | 25 | $603,000 |
| Seagen Inc. | 41 | $244,387 |
| Astrazeneca UK Limited | 4 | $164,197 |
| Beigene, Ltd. | 20 | $104,575 |
| Pfizer | 1 | $37,210 |
| Genentech, Inc. | 13 | $33,760 |
| Incyte Corporation | 57 | $32,538 |
| Y-mabs Therapeutics, Inc. | 23 | $23,854 |
| Regeneron Healthcare Solutions, Inc. | 11 | $17,641 |
| Shionogi Inc | 4 | $5,990 |
| Genmab U.S., Inc. | 1 | $5,950 |
| Sanofi | 1 | $3,245 |
| Eisai Inc. | 1 | $1,785 |
| Clinigen, Inc. | 3 | $380 |
| Iovance Biotherapeutics, Inc. | 2 | $274 |
| Novartis | 4 | $207 |
| GE HealthCare | 2 | $204 |
| AbbVie | 1 | $139 |
| Delcath Systems | 1 | $125 |
| Amgen | 1 | $101 |
| Array Biopharma Inc | 1 | $55 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KIMMTRAK$9,648
- TRINAV INFUSION SYSTEM$4,497
- LIBTAYO$3,111
- LENVIMA$1,785
- KEYTRUDA$310
- Proleukin$290
- Amtagvi$274
- ALLODERM$139
- Hepzato Kit$125
How this compares
$21,609,502 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocortisone | 55 | $2,149 |
| Oxycodone Hcl | 23 | $268 |
| Levothyroxine Sodium | 25 | $254 |
| Prednisone | 40 | $138 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Pittsburgh
- Jason LukePittsburgh$15M
- Leonard ApplemanPittsburgh$12.8M
- Jing Zhou HouPittsburgh$11.9M
- Taofeek OwonikokoPittsburgh$9.7M
- Ahmad TarhiniPittsburgh$7.4M
- Samuel JacobsPittsburgh$6.5M
- Cyrus KhanPittsburgh$4.5M
- Kathleen DorritiePittsburgh$3.2M
- Salman FazalPittsburgh$2.9M
- Mounzer AghaPittsburgh$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.